Medicamen Biotech share price & results
- Jun 2026
- Sept 2026
New Delhi-based pharma manufacturer of oncology and other generic formulations, running three WHO-GMP/US-FDA/EU-GMP plants and exporting to 35+ countries.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 43.9 | +14.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 10.9 | +0.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.5 | +54.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 4.43 | +0.4 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -19.08 | −12.8 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 24.67 | +30.4 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −25.4% 1Y
1Y: ₹353.6 on 24 Oct 2025 → ₹263.8. High ₹415.95 (25 Nov 2025), low ₹219.88 (17 Aug 2026).
- Previous close
- ₹263
- Market cap
- ₹375 Cr
- 52-week range
- ₹219.88 – ₹415.95
- One year
- −26.27%
- Price to earnings (TTM to Jun 2026)
- 34.59×
- Return on equity (TTM to Jun 2026)
- 4.43%
Overview
- Symbol
- NSE:MEDICAMEQ
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Medicamen Biotech Limited does
Based on the company's own presentations, annual report and earnings calls.
Medicamen Biotech Limited is a fully integrated pharmaceutical company with in-house R&D, API manufacturing and finished-dosage formulation capability, established in December 1993. It manufactures oncology therapeutics (under the Vivo Oncology brand) and other generics spanning cardiology, CNS, diabetology, anti-malarials, vitamins, antibiotics and pain management, sold across regulated and semi-regulated export markets in Latin America, Africa, Asia-Pacific and the Middle East. Its subsidiary Medicamen Life Sciences Private Limited (est. August 2022) markets a portfolio of tablets, capsules and syrups directly in the domestic Indian market.
Segments
- Oncology formulations
- General formulations / generics
- Domestic marketing (India)
- Research & Development
- Manufacturing plants
- 3 (Bhiwadi, Rajasthan; Haridwar Unit I & Unit II, Uttarakhand)
- Total manufacturing area
- ~2,77,000 sq. ft. across three plants (2,10,000 + 32,000 + 35,000 sq. ft.)
- Countries served
- 35+
- Product portfolio
- 100+ pharmaceutical offerings
- Products registered
- 160
- Products under registration/filing
- 250
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +54% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 43 | 41 | 26 | 38 | 42 | 43 | 55 | 44 |
| Expenses | 36 | 35 | 27 | 34 | 37 | 38 | 51 | 39 |
| Operating profit | 7 | 6 | -1 | 4 | 5 | 5 | 4 | 5 |
| Operating margin | 15.3% | 15.2% | −4.2% | 10.5% | 12.0% | 11.7% | 7.5% | 10.9% |
| Other income | 0 | 0 | 5 | 0 | 0 | 1 | 2 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 2 | 0 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 3 | 3 | 3 | 2 | 3 | 3 | 4 | 3 |
| Tax rate | 30.1% | 27.6% | 20.8% | 24.4% | 20.2% | 15.6% | 15.6% | 22.4% |
| Net profit | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 3 |
| EPS (₹ per share) | 1.79 | 1.98 | 1.90 | 1.21 | 1.63 | 1.91 | 2.19 | 1.87 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 141 | 172 | 151 | 179 |
| Expenses | 117 | 146 | 135 | 161 |
| Operating profit | 24 | 26 | 17 | 18 |
| Other income | 2 | 2 | 6 | 3 |
| Interest | 3 | 4 | 3 | 3 |
| Depreciation | 6 | 7 | 7 | 7 |
| Profit before tax | 17 | 17 | 13 | 12 |
| Net profit | 15 | 13 | 9 | 9 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 12 | 13 | 13 | 13 | 14 | 14 |
| Reserves | 136 | 181 | 196 | 205 | 262 | 266 |
| Borrowings | 26 | 26 | 30 | 27 | 39 | 38 |
| Other liabilities | 52 | 57 | 55 | 48 | 53 | 44 |
| Total liabilities | 226 | 277 | 294 | 293 | 367 | 362 |
| Fixed assets | 92 | 92 | 91 | 86 | 86 | 84 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 4 | 8 | 8 | 8 | 8 |
| Other assets | 131 | 180 | 195 | 199 | 273 | 270 |
| Total assets | 226 | 277 | 294 | 293 | 367 | 362 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 13 | 5 | -4 | 0 | -3 | -29 |
| Cash from investing | -18 | -8 | -8 | -9 | -2 | -3 |
| Cash from financing | 6 | 4 | 28 | 3 | -7 | 60 |
| Net cash flow | 1 | 1 | 17 | -6 | -11 | 28 |
| Free cash flow | -5 | -4 | -10 | -6 | -5 | -34 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 165 | 193 | 159 | 102 | 141 | 132 |
| Inventory days | 28 | 188 | 230 | 237 | 274 | 258 |
| Days payable | 161 | 291 | 232 | 152 | 182 | 138 |
| Cash conversion cycle | 32 | 91 | 157 | 188 | 234 | 252 |
| Working capital days | 130 | 146 | 151 | 117 | 186 | 197 |
| Return on capital employed | 13.0% | 12.0% | 11.0% | 10.0% | 7.0% | 6.0% |
| Dividend payout | 10.0% | 8.0% | 8.0% | 10.0% | 13.0% | 14.0% |
What the price assumes
Growth trapTo justify its price of ₹264, this stock must grow earnings at 28% every year for 7 years. Our analysis caps realistic growth at ~-20%. At that growth it is worth ₹20 — downside of 92%.
- Growth the price implies
- 28.4% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -17.7% a year
- net profit, FY23–FY26 · EPS -20.0%
- The gap
- 0.5 pp
- -92% downside if it only repeats history
Ownership
Who owns it
Public hold 55.00% as of Sept 2026; institutions added 4.02 pts since Jun 2026.
- Promoters 40.46%
- Foreign institutions 4.49%
- Domestic institutions 0.00%
- Government 0.05%
- Public 55.00%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 1.26% held
The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Medicamen Biotech Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 40.46% | unchanged | |
| 9.88% | unchanged | |
| 4.42% | unchanged | |
| 2.62% | unchanged | |
| 1.26% | newly disclosed | |
| 1.14% | unchanged | |
| 1.12% | unchanged | |
| — | off the list | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Medicamen Biotech Limited
Free account: one company. Everything above stays public.
Write why you follow Medicamen Biotech Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
- AL
ALBERTDAVDAlbert David Limited - HA
HALEOSLABSHALEOS LABS LIMITED - JE
JENBURPHJenburkt Pharmaceuticals Ltd. - AS
ASARFIASARFI HOSPITAL LIMITED - QM
QMSMEDIQMS Medical Allied Services Limited - AA
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited - TL
TLLTrident Lifeline Limited - NU
NURECANureca Limited
Learn to analyse Medicamen Biotech Limited
Guides on how to read this kind of business and the numbers that matter.